Vemurafenib in Langerhans cell histiocytosis: report of a pediatric patient and review of the literature

Selective BRAF inhibitors such as vemurafenib have become a treatment option in patients with Langerhans cell Histiocytosis (LCH). To date, only 14 patients receiving vemurafenib for LCH have been reported. Although vemurafenib can stabilize the clinical condition of these patients, it does not seem...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Oncotarget
Main Authors: Heisig, Anne, Sörensen, Jan, Zimmermann, Stefanie-Yvonne, Schöning, Stefan, Schwabe, Dirk, Kvasnicka, Hans-Michael, Schwentner, Raphaela, Hutter, Caroline, Lehrnbecher, Thomas
Format: Artigo
Jezik:Inglês
Izdano: Impact Journals LLC 2018
Teme:
Case Report
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5955145/
https://ncbi.nlm.nih.gov/pubmed/29774135
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.25277
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki